×
About 15,290 results

ALLMedicine™ Hypercholesterolemia Center

Research & Reviews  4,030 results

Estimated Yield of Screening for Heterozygous Familial Hypercholesterolemia With and Wi...
https://doi.org/10.1161/JAHA.121.025192
Journal of the American Heart Association; Bellows BK, Khera AV et. al.

May 19th, 2022 - Background Heterozygous familial hypercholesterolemia (FH) is a common genetic disorder causing premature cardiovascular disease. Despite this, there is no national screening program in the United States to identify individuals with FH or likely p...

Lipid metabolic genes and maternal supraphysiological hypercholesterolemia: an analysis...
https://doi.org/10.1210/clinem/dgac317
The Journal of Clinical Endocrinology and Metabolism; Cai X, Liang N et. al.

May 17th, 2022 - The joint associations of maternal and fetal single nucleotide polymorphisms (SNPs) of lipid metabolic genes with the risk of maternal supraphysiological hypercholesterolemia (MSPH) are unclear. This study aims to investigate the associations of m...

Screening of ABCG5 and ABCG8 Genes for Sitosterolemia in a Familial Hypercholesterolemi...
https://doi.org/10.1161/CIRCGEN.121.003390
Circulation. Genomic and Precision Medicine; Tada MT, Rocha VZ et. al.

May 14th, 2022 - Sitosterolemia is a rare autosomal recessive disorder caused by homozygous or compound heterozygous variants in ABCG5/ABCG8. The disease is characterized by increased plasma plant sterols. Small case series suggest that patients with sitosterolemi...

Reference values for the tri-ponderal mass index and its association with cardiovascula...
https://doi.org/10.1016/j.nut.2022.111656
Nutrition (Burbank, Los Angeles County, Calif.); Alvim RO, Siqueira JH et. al.

May 14th, 2022 - The aims of this study was to determine the cutoff values for tri-ponderal mass index (TMI) and investigate the association between overweight/obesity as classified by TMI and cardiometabolic risk factors in Brazilian adolescents aged 12 to 17 y. ...

A Study of the Efficacy and Safety of MK-0616 (Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-008)
https://clinicaltrials.gov/ct2/show/NCT05261126

May 13th, 2022 - The purpose of this study is to evaluate the efficacy and safety of MK-0616, an oral PCSK9 inhibitor, in lowering low-density lipoprotein cholesterol (LDL-C) in participants with hypercholesterolemia. The primary hypothesis is that at least one of...

see more →

Guidelines  7 results

The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines fo...
https://doi.org/10.1530/EJE-21-0479
European Journal of Endocrinology; Bartalena L, Kahaly GJ et. al.

Jul 24th, 2021 - Graves' orbitopathy (GO) is the main extrathyroidal manifestation of Graves' disease (GD). Choice of treatment should be based on the assessment of clinical activity and severity of GO. Early referral to specialized centers is fundamental for most...

Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Up...
https://doi.org/10.1016/j.cjca.2018.09.005
The Canadian Journal of Cardiology; Brunham LR, Ruel I et. al.

Dec 12th, 2018 - Familial hypercholesterolemia (FH) is the most common monogenic disorder causing premature atherosclerotic cardiovascular disease. It affects 1 in 250 individuals worldwide, and of the approximately 145,000 Canadians estimated to have FH, most are...

Joint position statement on "Nutraceuticals for the treatment of hypercholesterolemia" ...
https://doi.org/10.1016/j.numecd.2016.11.122
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD; Pirro M, Vetrani C et. al.

Dec 14th, 2016 - Evidence showed that LDL-cholesterol lowering is associated with a significant cardiovascular risk reduction. The initial therapeutic approach to hypercholesterolemia includes dietary modifications but the compliance to recommendations is often in...

Screening for Lipid Disorders in Children and Adolescents: US Preventive Services Task ...
https://doi.org/10.1001/jama.2016.9852
JAMA , Bibbins-Domingo K et. al.

Aug 18th, 2016 - Elevations in levels of total, low-density lipoprotein, and non-high-density lipoprotein cholesterol; lower levels of high-density lipoprotein cholesterol; and, to a lesser extent, elevated triglyceride levels are associated with risk of cardiovas...

Screening for Abdominal Aortic Aneurysm: Clinical Summary of USPSTF Recommendation
https://allmedx.com/USPSTFPDF/abdomansumm.pdf

Jun 17th, 2014 - SCREENING FOR ABDOMINAL AORTIC ANEURYSM CLINICAL SUMMARY OF U.S. PREVENTIVE SERVICES TASK FORCE RECOMMENDATION Population Men ages 65 to 75 years who have ever smoked* Men ages 65 to 75 years who have never smoked Women ages 65 t...

see more →

Drugs  1,013 results see all →

Clinicaltrials.gov  268 results

A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation II
https://clinicaltrials.gov/ct2/show/NCT05333107

May 13th, 2022 - In this study, the study drug 'NNC0385-0434' will be tested in 3 different tablet formulations. These formulations are being tested for the treatment of hypercholesterolemia (high cholesterol). Participants will only receive 2 of the 3 tablet form...

A Study of the Efficacy and Safety of MK-0616 (Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-008)
https://clinicaltrials.gov/ct2/show/NCT05261126

May 13th, 2022 - The purpose of this study is to evaluate the efficacy and safety of MK-0616, an oral PCSK9 inhibitor, in lowering low-density lipoprotein cholesterol (LDL-C) in participants with hypercholesterolemia. The primary hypothesis is that at least one of...

Long Term Post Marketing Specified Drug Use Result Survey for Evolocumab in Japan
https://clinicaltrials.gov/ct2/show/NCT02808403

May 11th, 2022 - The objectives of study are to 1) determine the incidence of adverse events and adverse drug reactions among patients receiving evolocumab for up to 2 years, and 2) identify and describe patient characteristics (e.g. demographics, medical history)...

Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia
https://clinicaltrials.gov/ct2/show/NCT04579367

May 10th, 2022 - This non-interventional study will be conducted to characterize the risks and benefits of bempedoic acid and/or its fixed-dose combination with ezetimibe in a real-world clinical setting in adult patients with primary hypercholesterolaemia or mixe...

Effect of Breastfeeding on Lipid Profile and Cardiovascular Risk Markers in Women With Familial Hypercholesterolemia
https://clinicaltrials.gov/ct2/show/NCT05367310

May 10th, 2022 - Patients with familial hypercholesterolemia (FH) have elevated plasma levels of LDL-cholesterol from first years of life. Cholesterol burden through life defines risk of cardiovascular disease. In women with FH, cholesterol levels increase during ...

see more →

News  792 results

Managing TIA: Early action and essential risk-reduction steps
https://www.mdedge.com/familymedicine/article/254459/preventive-care/managing-tia-early-action-and-essential-risk-reduction
MDedge Family Medicine; Kristen Rundell, MD, Shalina Nair, MD, MBA

May 10th, 2022 - As many as 240,000 people per year in the United States experience a transient ischemic attack (TIA),1,2 which is now defined by the American Heart Association and American Stroke Association as a “transient episode of neurological dysfunction cau.

New HIV Care Guidelines From the European AIDS Clinical Society
https://www.medscape.com/viewarticle/973524

May 5th, 2022 - Version 11.0 of the 2021 revised European AIDS Clinical Society (EACS) Guidelines updates all aspects of HIV care and adds recommendations on COVID-19 and antiretroviral treatment (ART) in children and adolescents, the guidelines authors report in...

Seven Factors Account for 85% of Acute MI Risk in Young Americans
https://www.medpagetoday.com/cardiology/prevention/98522

May 3rd, 2022 - Seven risk factors, some modifiable and some not, accounted for the vast majority of risk for first-time acute myocardial infarction (MI) in young adults, according to a case-control study. The seven factors -- diabetes, depression, hypertension, ...

The Best Statins to Lower Non-HDL Cholesterol in Diabetes?
https://www.medscape.com/viewarticle/972109

Apr 13th, 2022 - A network meta-analysis of 42 clinical trials concludes that rosuvastatin, simvastatin, and atorvastatin are the statins most effective at lowering non-high-density-lipoprotein cholesterol (non-HDL-C) in people with diabetes and at risk for cardio...

Many on Medicare Can't Afford to Fill Cancer Rx
https://www.medscape.com/viewarticle/971953

Apr 11th, 2022 - Many Medicare beneficiaries without low-income subsidies do not fill high-price specialty drug prescriptions, new research shows. For the four conditions studied — cancer, hepatitis C, immune system disorders, and hypercholesterolemia — researcher...

see more →

Patient Education  6 results see all →